Strategic Focus

Built for Advanced Therapeutics.
Deployed Upstream.

Following strategic review, Zenphia has sharpened its positioning around five core priorities that maximize credibility, deal flow, and long-term platform value.

01
Narrow to Advanced TherapeuticsGene therapy, biologics, oncology, rare disease — deepest unmet need, highest IP and regulatory complexity.
02
Partner with InstitutionsUniversities, AMCs, national labs — scalable, repeatable pipeline with stronger investor credibility.
03
Structured Lab-to-Venture PipelineMilestone-gated pathway with defined gates — reduces structural failure, creates predictable deal flow.
04
Co-Builder Equity ModelEquity participation from formation — aligns Zenphia's success with portfolio company outcomes.
05
Flagship Portfolio as ProofVectorGen demonstrates the full model in action — building investor confidence through execution.

Our Philosophy

Infrastructure
Deployed Upstream.

In life sciences, sequence matters. IP strategy must inform the regulatory pathway. The regulatory pathway must inform clinical design.

When these decisions are made in silos by disconnected specialists, structural failure is inevitable. When they are integrated by a single partner who understands the complete path from lab to market, breakthrough science actually reaches the world.

"Founders don't fail for lack of ambition or expertise. They fail for lack of integrated execution infrastructure deployed at the right time."

— Peter Yassopoulos, Founder & CEO

The Ecosystem Is Broken by Design

97% of life sciences research never reaches patients — not because the science fails, but because the infrastructure around it does.

Our Mission